Cinctive Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Cinctive Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-90,000	Closed	-$3.45M	–	470
2022 Q2	$3.45M	Buy	90,000 +15,000	+20%	+$474K	0.14%	228
2022 Q1	$3.1M	Buy	+75,000	New	+$2.32M	0.12%	264

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cinctive Capital Management's AXSM Position: Q2 2026 in Review

Cinctive Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 11,121 shares worth $2.72M. The stake represents 0.1% of the portfolio and ranks #246 among its holdings.

506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Cinctive Capital Management held 11,121 shares of Axsome Therapeutics worth $2.72M as of Q2 2026.
Axsome Therapeutics was a new Cinctive Capital Management position in Q2 2026.
Axsome Therapeutics made up 0.1% of Cinctive Capital Management's portfolio in Q2 2026, its #246 holding.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.